David joined Immunocore in September 2018 to advance the company's lead candidate, IMCgp100, towards commercialisation and progress Immunocore's growing pipeline of TCR candidates through clinical development.
Over his career, Berman has worked on immuno-oncology programmes at all stages of development including leadership roles in developing four approved biologics.
Most recently, Berman was senior vice president and Head of the AstraZeneca Immuno-oncology Franchise, where he was responsible for the strategy and execution of the company's late stage I-O programme.
Prior to that, he was head of the early stage oncology programme at MedImmune. David has also held senior development roles at Bristol-Myers Squibb including Head of the Immuno-oncology exploratory development team and global clinical lead for the first approved IO checkpoint inhibitor and one of the first monoclonal antibodies approved for myeloma.
In addition to the development of CTLA4 and PD1/L1 checkpoint inhibitors, Berman's experience includes developing a wide range of novel IO targets and combinations as well as translational medicine focused on their mechanisms of action.
Berman completed his MD at the University of Texas Southwestern Medical School and his PhD in the Laboratory of Dr. Alfred G. Gilman, the 1994 Nobel laureate for his discovery of G-proteins. He completed a residency in Anatomic Pathology at the National Cancer Institute and a Fellowship at The Johns Hopkins University School of Medicine.
Immunocore, a leading T Cell Receptor biotechnology company, is focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases.
The company's primary therapeutic focus is oncology and it also has programmes in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programs in development and the lead programme, IMCgp100, has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma.
Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with an office outside Philadelphia, USA. The company is privately held by a broad international investor base.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer